Timing of ctDNA Testing in Advanced Breast Cancer
Recruiting · NCT07681323 · Observational (researchers observe without assigning treatment) · Lead sponsor: Geneplus-Beijing Co. Ltd.
View the official record on ClinicalTrials.gov →What this trial is about
This multicenter, prospective observational cohort study aims to investigate the impact of circulating tumor DNA (ctDNA) level and key actionable gene mutation status on prognosis and treatment response in patients with advanced breast cancer.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Histologically confirmed advanced breast cancer
- Age ≥18 years
- Expected survival \>3 months
- Willing to undergo ctDNA testing and sign informed consent form
Exclusion criteria
- The subject has not signed the informed consent form.
- Pregnant or breastfeeding women.
- Other situations deemed by the investigator as unsuitable for inclusion in the study.
Where it is running
1 location listed.
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences - Beijing, China